Fingolimod (Gilenya®)

Assessment Status Full Assessment Complete
Drug Fingolimod
Brand Gilenya®
Indication For the treatment of highly active relapsing-remitting multiple sclerosis.
Assessment Process
Rapid review commissioned 03/12/2010
Rapid review completed 03/01/2011
Rapid review outcome Full Pharmaconomic Evaluation Recommended
Full pharmacoeconomic assessment commissioned by HSE 03/06/2011
NCPE assessment completed 20/09/2011
NCPE assessment outcome Reimbursement not recommended at the submitted price.

22nd September 2011

Following a price revision we now consider Fingolimod (Gilenya®) a cost-effective therapy for the treatment of relapsing-remitting multiple sclerosis patients in the Irish healthcare setting.


Technical Summary